116 related articles for article (PubMed ID: 1780683)
21. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients.
Fioretti P; Gadducci A; Ferdeghini M; Prontera C; Malagnino G; Facchini V; Mariani G; Bianchi R
Gynecol Oncol; 1992 Feb; 44(2):155-60. PubMed ID: 1544592
[TBL] [Abstract][Full Text] [Related]
22. Concentration of tumor-associated trypsin inhibitor (TATI) in pleural effusions.
Klockars M; Pettersson T; Fröseth B; Selroos O; Stenman UH
Chest; 1990 Nov; 98(5):1159-64. PubMed ID: 2225961
[TBL] [Abstract][Full Text] [Related]
23. Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy.
Huhtala ML; Kahanpää K; Seppälä M; Halila H; Stenman UH
Int J Cancer; 1983 Jun; 31(6):711-4. PubMed ID: 6190763
[TBL] [Abstract][Full Text] [Related]
24. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.
Plebani M; Basso D; Fabris C; Meggiato T; Del Favero G; Panozzo MP; Fogar P; Faggian D; Angonese C; Burlina A
Klin Wochenschr; 1989 Oct; 67(20):1029-32. PubMed ID: 2586008
[TBL] [Abstract][Full Text] [Related]
25. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer.
Kasurinen A; Laitinen A; Kokkola A; Stenman UH; Böckelman C; Haglund C
Acta Oncol; 2020 Jun; 59(6):681-688. PubMed ID: 32124669
[No Abstract] [Full Text] [Related]
26. Effect of intracavitary radiotherapy on tumor-associated trypsin inhibitor (TATI) in patients with cervical and endometrial cancer.
Lehtovirta P; Turpeinen U; Stenman UH
Gynecol Oncol; 1990 Jul; 38(1):110-3. PubMed ID: 2354815
[TBL] [Abstract][Full Text] [Related]
27. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
Catarino M; Conde R
Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
[TBL] [Abstract][Full Text] [Related]
28. Tumor-associated trypsin inhibitor (TATI) in pleural effusions.
Rapellino M; Pecchio F; Baldi S; Adamo MR; Macri M; Ricardi G
Scand J Clin Lab Invest Suppl; 1991; 207():47-9. PubMed ID: 1780690
[TBL] [Abstract][Full Text] [Related]
29. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
30. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum inhibin and tumor-associated trypsin inhibitor concentrations in a young woman with dysgerminoma of the ovary.
Santala M; Burger H; Ruokonen A; Stenbäck F; Kauppila A
Gynecol Oncol; 1998 Dec; 71(3):465-8. PubMed ID: 9887252
[TBL] [Abstract][Full Text] [Related]
32. Validation and comparison of tumor-associated trypsin inhibitor (TATI) immunoassays.
Janeiro E; Guimarães J; Stenman UH; Catarino M; Itkonen O
Clin Chim Acta; 2012 Aug; 413(15-16):1244-8. PubMed ID: 22507084
[TBL] [Abstract][Full Text] [Related]
33. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma.
Goumas PD; Mastronikolis NS; Mastorakou AN; Vassilakos PJ; Nikiforidis GC
ORL J Otorhinolaryngol Relat Spec; 1997; 59(2):106-14. PubMed ID: 9166881
[TBL] [Abstract][Full Text] [Related]
35. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients.
Lukkonen A; Lintula S; von Boguslawski K; Carpén O; Ljungberg B; Landberg G; Stenman UH
Int J Cancer; 1999 Nov; 83(4):486-90. PubMed ID: 10508484
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the tumor-associated trypsin inhibitor (TATI) marker in patients with carcinoma of the uterine body 17 years after treatment.
Kozakiewicz B; Chadzyńska M; Dmoch-Gajzlerska E
Eur J Gynaecol Oncol; 2014; 35(1):39-43. PubMed ID: 24654459
[TBL] [Abstract][Full Text] [Related]
37. Tumor-associated trypsin inhibitor and cancer antigen 125 in pelvic masses.
Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1990 Aug; 38(2):170-4. PubMed ID: 2167279
[TBL] [Abstract][Full Text] [Related]
38. Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma.
Gion M; Mione R; Tremolada C; Dalla Palma P; Ruol A; Dittadi R; Leon A; Nosadini A; Castoro C; Bruscagnin G
Scand J Clin Lab Invest Suppl; 1991; 207():37-41. PubMed ID: 1780688
[TBL] [Abstract][Full Text] [Related]
39. Serum tumour-associated trypsin inhibitor (TATI) and renal function.
Tramonti G; Donadio C; Ferdeghini M; Annichiarico C; Norpoth M; Bianchi R; Bianchi C
Scand J Clin Lab Invest; 1996 Nov; 56(7):653-6. PubMed ID: 8981662
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer.
Hotakainen K; Bjartell A; Sankila A; Järvinen R; Paju A; Rintala E; Haglund C; Stenman UH
Int J Oncol; 2006 Jan; 28(1):95-101. PubMed ID: 16327984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]